Trailing Akero and 89bio, Boston Pharmaceuticals posts early data on its NASH injection
In an early-stage study, Boston Pharmaceuticals’ injection reduced indicators of NASH, a fatty liver disease. The treatment is one of a handful of investigational drugs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
